Skip to main content
. 2022 Nov 29;12:1001503. doi: 10.3389/fonc.2022.1001503

Figure 4.

Figure 4

(A) Efficacy (on OS) and safety (≥3 AE). (B) Efficacy (on PFS) and safety (≥3 AE). OS, overall survival; AE, adverse event; PFS, progression-free survival.